Introduction {#Sec1}
============

Umbilical cord blood (UCB) is increasingly used as an alternative source of hematopoietic stem and progenitor cells (HSC/HPC) to bone marrow and mobilized peripheral blood for HSC transplantation in both children and adults \[[@CR1], [@CR2]\]. It has the advantage that it can be tissue typed, screened for viral biomarkers, processed and banked, especially ahead of urgent or directed transplants, without the attrition rate that occurs with bone marrow donors \[[@CR1]--[@CR4]\]. Of note, a recent report states that strategic objectives for the UK NHSBT Cord Blood Bank (CBB) are maximized clinical benefits and inventory utilization where a feasible target is 1% annual utilization of banked UCB units \[[@CR5]\].

UCB and the umbilical cord itself have been reported to contain other stem/progenitor cell types, including mesenchymal stem/stromal cells and endothelial progenitor cells \[late endothelial outgrowth cells or endothelial colony forming cells (ECFC)\]. These overall types may have the potential to improve transplant outcomes when used in conjunction with HSC \[[@CR6], [@CR7]\]. Although ECFC are found in umbilical cord tissue (HUVEC) and UCB at higher levels and with higher proliferative potential than in adult peripheral blood \[[@CR8]--[@CR10]\], factors affecting their yield and recovery from neonatal sources are still not understood. In contrast, since the first UCB HSC transplant in 1988 \[[@CR11]\], a great deal of knowledge has been acquired on the optimal selection of UCB units for HSC transplantation \[[@CR12], [@CR13]\]. This is based on obstetric factors (Table [1](#Tab1){ref-type="table"}), total nucleated cell content (TNC), CD34^+^ cell count, HLA and blood group matching of the recipient and donor plus processing, storage and testing procedures. Other quality measurements such as maternal HLA typing to assess the donor's non-inherited maternal HLA-antigens may also influence transplant success \[[@CR1], [@CR2], [@CR12]\]. Typically, UCB is collected from a wide range of donors, held for a period of time (not exceeding 24--48 h) at 22 ± 2°C prior to processing, and then cryopreserved under controlled rate freezing conditions and stored long-term below −150°C (as recommended by international accreditation agencies such as FACT-Netcord) \[[@CR1], [@CR2], [@CR8]\]. Units are also analyzed before or after processing for TNC, CD34^+^ cell numbers and hematopoietic colony forming units \[[@CR1], [@CR8], [@CR12]--[@CR14]\]. Obstetric factors that have previously been reported to affect TNC and/or HSC/HPC (CD34^+^ cells and total CFU) content include birth and placental weight, infant gender, parity of the mother, nucleated red cell content, low venous pH, prolonged first stage of labor and Apgar scores \[quantifies the ability of the infant to adapt to the extra uterine environment and hence a measurement of the health of newborn infants at 1, 5 and 10 min post birth (Apgar~1min~, Apgar~5min~, Apgar~10min~) with the normal Apgar score varying from 7 to 10\].Table 1Obstetric factors influencing volume, TNC count and HPC recovery from UCBObstetric factorHigh volume UCBTNCCD34^+^ contentGranulocyte--macrophage progenitors (colony-forming units)Sex of babyFemale \[[@CR33]--[@CR38]\]Male \[[@CR35], [@CR38], [@CR39]\]Male \[[@CR35], [@CR38], [@CR39]\]Birth weight(+) \[[@CR36], [@CR37], [@CR39]--[@CR41]\](+) \[[@CR34], [@CR36], [@CR38], [@CR42]\](+) \[[@CR22], [@CR36], [@CR37], [@CR41], [@CR43]\](+) \[[@CR36], [@CR37], [@CR41], [@CR43]\]Placental weight(+) \[[@CR33], [@CR36], [@CR39]--[@CR41]\](+) \[[@CR36], [@CR38], [@CR39]\](+) \[[@CR41]\](+) \[[@CR41]\]Gestational age(+) \>40 weeks \[[@CR33], [@CR40]\](+) \[[@CR22], [@CR37]--[@CR39]\](+) \>39 weeks \[[@CR36]\] (however, no consensus in the literature)(+) full-term infants \[[@CR44]\] (however, no consensus in the literature)(+) Standard (38--40 week) versus non-standard gestation \[[@CR34]\](−) \[[@CR37]\], (+) \[[@CR37], [@CR44]\]Length of labor(+) \[[@CR40]\](+) First \[[@CR45]\] or second \[[@CR39], [@CR45]\] stage of labor(+) First and/or second stage of labor \[[@CR45]\]Delivery(+) Caesarian \[[@CR33], [@CR36], [@CR46]\](+) Assisted delivery^a^ \[[@CR38]\](+) Assisted delivery^a^ \[[@CR45]\](+) Induction of labor \[[@CR40]\](+) Vaginal *c.f.* caesarean \[[@CR36], [@CR42], [@CR47]\](+) Caesarean delivery \[[@CR44]\]Parity(+) Previously nulliparous^b^ mothers \[[@CR22]\](+) Fewer previous pregnancies \[[@CR22], [@CR34], [@CR45], [@CR48]\](+) Previously nulliparous^b^ mothers \[[@CR22], [@CR45]\]Meconium in amniotic fluid?(+) \[[@CR33]\](+) \[[@CR33], [@CR39]\]Maternal age(+) \>25 years \[[@CR42]\](−) \[[@CR37]\]Apgar score(−) \[[@CR45]\](−) \<7 \[[@CR39], [@CR45]\]Umbilical cord(+) Nuchal cord^c^ \[[@CR40]\](+) Cord length \[[@CR37], [@CR40]\]Multiple births(+) \[[@CR40]\]Maternal diabetes mellitus(+) \[[@CR40], [@CR43], [@CR49]\]Correlations are shown as (+) positive or (−) negative; ^a^ Vaginal but not spontaneous deliveries which require induction of labor or obstetric intervention for delivery; ^b^ Has never given birth; ^c^ Umbilical cord looped around baby's neck

It remains uncertain how this knowledge of UCB HSC/HPC quality and storage affects the late endothelial outgrowth cell/ECFC content of UCB. A recent report indicates that pre-term UCB units at 28--35 weeks of gestation contain \~fourfold more ECFCs than term UCB \[[@CR15]\], yet no other obstetric features were examined. Additionally, studies on ECFC recovery after UCB cryopreservation are conflicting, with Lin et al. \[[@CR16]\] indicating that the outgrowth endothelial cell content is not statistically different between cryopreserved and fresh UCB mononuclear cells although on average fewer were recovered after cryopreservation, while Vanneaux et al. \[[@CR17]\] recovered significantly fewer ECFC from cryopreserved than from fresh UCB units.

In order to achieve optimal ECFC yields from UCB at term deliveries, we set out to determine (1) how to best select UCB donors based on obstetric factors, (2) whether storage temperatures of UCB units using current standards for UCB HSC/HPC of 22 ± 2°C prior to processing was superior to storage at 4°C, and (3) whether ECFC content was compromised following cryopreservation. As with HSC/HPC transplants, an understanding of optimal donor selection, short-term storage conditions of whole UCB before processing and long-term storage conditions of cryopreserved UCB may in the future enhance the efficacy of UCB ECFC for therapeutic use.

Materials and methods {#Sec2}
=====================

Materials {#Sec3}
---------

Wash buffer A consisted of Hank's buffered salt solution (HBSS) without calcium and magnesium (Lonza Biologics, Slough, England) supplemented with 3 g/l sodium citrate and 0.5% (v/v) Hyclone fetal calf serum (FCS; Thermo Scientific, Loughborough, England). Wash buffer B consisted of HBSS without calcium and magnesium (Lonza Biologics). Growth medium ('complete EGM-2') comprised EBM-2 media supplemented with all components of the SingleQuot Bullet Kit \[hydrocortisone, human epidermal growth factor, human fibroblast growth factor-basic, insulin-like growth factor-1, vascular endothelial growth factor, ascorbic acid, heparin, gentamicin, 2% (v/v) FCS\] (Lonza Biologics) and then further supplemented with 8% (v/v) Hyclone FCS and 1% (v/v) penicillin/streptomycin (PAA Laboratories Ltd., Yeovil, England). Bovine DNase I (Sigma--Aldrich Ltd., Poole, England) was prepared in 50% (v/v) glycerol, 5 mM CaCl~2~ in HBSS (pH 7.8) and stored at −20°C. 'Thaw buffer' consisted of growth media with 10 U/ml DNase I. Forty eight- and 6-well tissue culture plates pre-coated with type-1 rat tail collagen were purchased from BD Biosciences (Oxford, England). Other cell culture vessels were from Corning (Lowell, MA, USA), 0.5% (w/v) trypsin and 0.2% (w/v) EDTA (trypsin--EDTA) from PAA Laboratories Ltd., 0.4% (w/v) trypan blue from Invitrogen Ltd. (Paisley, Scotland) and F~C~ Receptor Blocking Reagent from Miltenyi-Biotec. (Bergisch-Gladbag, Germany). Unless otherwise specified, incubations were at 37°C in a humidified incubator with 5% CO~2~ in air. Accuspin tubes containing Ficoll-Histopaque-1077 (1.077 g/ml), Fungizone and all other materials were obtained from Sigma--Aldrich Ltd.

Umbilical cord blood collection {#Sec4}
-------------------------------

Fresh UCB was collected by the NHSBT Cord Blood Resource team (Oxford, England) (termed 'R&D UCB') with informed written consent from mothers at the John Radcliffe Hospital, Oxford in accordance with Oxfordshire Research Ethics Committee approval. These mothers were over the age of 18, had uncomplicated births, screened negative at the time of delivery for a range of infections (e.g. HIV, HBV, HCV, syphilis), did not use illegal drugs and were not delivering at prematurity (\<36 weeks). Further exclusion criteria were known genetic defects of the baby (e.g. Down's syndrome, Spina Bifida) due to the requirement for diagnostic placental specimens and to reduce maternal distress. Due to other research projects taking place at this hospital, no pre-eclampsic mothers donated to this study. UCB was collected directly from the umbilical cord as soon as possible after delivery of the placenta by needle cannulation into sterile UCB collection bags containing 21 ml citrate phosphate dextrose anticoagulant (MacoPharma Ltd., Twickenham, England). Cell counts from a sample of UCB from the bag were analyzed using a Sysmex total blood analyzer (Sysmex XE-2100, Sysmex UK Ltd., Milton Keynes, England). Samples were anonymised prior to being made available to researchers. Obstetric observations were obtained from archived data by the Oxford-Radcliffe Hospital Information Service by certified staff not involved in the research.

Mononuclear cells (MNC) were isolated from UCB by centrifugation on Ficoll-Histopaque (density 1.077 g/ml) using Accuspin tubes as per the manufacturer's instructions. The resulting buffy coat was resuspended in wash buffer A and sedimented once at 400×*g* to remove Ficoll, once at 200×*g* to reduce platelet contamination and finally sedimented at 400×*g*. The resulting pellet was washed with complete EGM-2 then sedimented at 200×*g*. R&D UCB MNC were cryopreserved in Hyclone FCS containing 10% (v/v) DMSO in Nunc cryovials using a Nalgene Mr. Frosty cryopreservation chamber at −80°C. After at least 4 h, cryovials were transferred to the gas-phase of liquid nitrogen storage.

UCB destined for banking for unrelated transplants is stored by the NHSBT Cord Blood Bank (termed 'CBB UCB'). The UCB for this purpose was collected in 2004--2005 by methods similar to above and described in detail elsewhere \[[@CR4]\]. UCB processing was carried out within 24 h of UCB collection and differs from the R&D procedure above in that whole UCB was volume reduced to 21 ml and depleted of plasma and erythrocytes using the Biosafe Sepax system \[[@CR3], [@CR18]\]. The UCB buffy coat was then cryopreserved using DMSO and stored in a BioArchive. CD34^+^ cells were enumerated by flow cytometry using the ISHAGE protocol. The starting volumes and TNC of CBB UCB units were similar to R&D UCB units (Table [2](#Tab2){ref-type="table"}). Of the UCB units used here, the majority were made available for research because consent was specifically given to donate to research but not banking (63%). Other reasons were low TNC (5%) and failure to complete 12 week follow up interviews necessary for banking (32%).Table 2Characteristics of UCBCharacteristicCBB UCBR&D UCBVolume (ml)67 ± 589 ± 4TNC × 10^7^ (/UCB unit)82 ± 1277 ± 1MNC × 10^6^ (/ml)39.4 ± 6.0^a^8.1 ± 0.7CD34^+^ × 10^6^ (/UCB unit)2.7 ± 0.8n/an1930^a^CBB UCB units are volume reduced to 21 ml for processing whereas R&D UCB units are not. Error is SEM

Recovery of MNC from cryopreservation {#Sec5}
-------------------------------------

Cryopreservation vials were removed from gas-phase liquid nitrogen, briefly stored in dry ice and then thawed rapidly at 37°C in a waterbath. Without delay, the volume of thawed MNC volume was doubled over 1 min by gradual drop-wise addition of warm (37°C) thaw buffer with gentle mixing. Five further volumes of warm thaw buffer were then added, mixed gently and incubated at 37°C for 30 min with DNase 1 in a sealed tube. Cells were pelleted by centrifugation at 22°C for 10 min at 200×*g*. Supernatant was aspirated (90% of total volume) and cells resuspended by gentle pipetting.

Endothelial cell culture and enumeration of primary endothelial colony forming cells {#Sec6}
------------------------------------------------------------------------------------

UCB MNCs were plated at 2 × 10^7^ MNCs/well in 4 ml complete EGM-2 into rat collagen 1-coated 6-well plates and grown for 24 h at which time cultures were then washed gently three times with wash buffer B to remove unattached cells and debris, before feeding with complete EGM-2. Growth medium was changed daily for six further days, then every second day from d8 to d14. ECFC-derived colonies based on those with endothelial morphology were counted on d14 using light microscopy (Nikon Eclipse TS100, Nikon Ltd., London, England) and contained \>50 cells/colony. ECFC frequency was enumerated in three ways (A) per UCB unit, (B) per ml of UCB and (C) normalized per 10^6^ MNC seeded. At this time, these primary colonies were defined as passage 0 (p0), and a passage number incremented with each subsequent trypsination and subculture.

At d14, cultures were gently washed three times with wash buffer B to remove all media and debris and individual colonies isolated by incubation with trypsin--EDTA for 10 min or until completely detached. Where necessary to avoid non-endothelial morphology cells (e.g. single attached cells, striated cells), cloning rings were used to isolate endothelial colonies. ECFC-derived colonies (on average 10 per culture) were pooled and seeded into a T75 flask (75 cm^2^ surface area) in 30 ml of complete EGM-2. When cells reached approximately 90% confluency, they were subcultured again as follows. T75 flasks were washed three times with 30 ml of Dulbecco's phosphate wash buffered saline (DPBS) (Lonza Biologics) to remove all residual complete media and serum. Cells were incubated with 3 ml trypsin--EDTA for 10 min or until they were completely detached from the flask. Cells were split at a dilution rate to give 90% confluency 4--5 days later. The endothelial nature of the ECFC-derived cells was confirmed by morphology and phenotypic analysis as described \[[@CR19]\].

Proliferative potential of endothelial colony forming cells {#Sec7}
-----------------------------------------------------------

Proliferative potential of ECFC was measured in the clonogenic endothelial colony-formation assay as described previously \[[@CR19]\]. Briefly, pooled p1 endothelial colonies (d14) from each UCB harvest were pooled, diluted to give 0.5 cells/well by limiting dilution and manual pipetting in collagen-coated 96-well plates in 100 μl complete EGM-2 and grown for 14 days with complete media replacement every 3--5 days. On d14 colonies were examined microscopically and by Calcein AM staining and scored. Primary colonies were scored as previously described as high proliferative potential (HPP) (\>2,000 cells/colony), low proliferative-potential (LPP) (50--2,000 cells/colony or disregarded as endothelial clusters (\<50 cells/colony) \[[@CR19]\].

Statistical analyses {#Sec8}
--------------------

Statistical analysis of the effect of obstetric factors consisted of transforming the data to give a normal distribution. In the generalized linear model, framework discriminant analysis was carried out by fitting a binary regression analysis using R statistical package. Other tests of statistical significance were performed with the software program, Prism (GraphPad, Version 5, San Diego, USA).

Results {#Sec9}
=======

Obstetric and demographic factors analyzed {#Sec10}
------------------------------------------

Obstetric factors have proven useful as selection criteria for UCB units for HSC transplantation. A similar approach was taken here for assessing ECFC content in UCB units in this study. Many factors are known about the mother and baby before the delivery (prenatal), at the time of the delivery (perinatally) and shortly after the delivery at the time of UCB collection, selection and processing (postnatally). Prenatal factors examined were maternal parity, gravidity, age, ethnic group, sex of the baby and gestation period. Perinatal factors examined were the duration of labor and the stages of labor, delivery method, route of delivery, weight of placenta, birth weight, ethnic group of baby and Apgar scores at 1, 5 and 10 min. Post natal features of UCB were volume of UCB, MNC concentration, TNC and nucleated red blood cell concentration.

To test whether obstetric factors had an effect on ECFC yield from UCB, ECFC were enumerated in 52 fresh R&D UCB units collected at random. Demographic information about the UCB donors is presented in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}. Of note, those collected for research purposes were dissimilar to national averages for cord blood banking regarding route of delivery, parity, gravidity, placental weight and ethnicity. Of the deliveries, 27% were vaginal, 71% were cesarean and 2% were a cesarean after first stage labor. This statistic reflects the nature of UCB collection of UCB units for research at the John Radcliffe Hospital, where cesarean sections present the best prospect for collecting UCB due to the increased opportunity for pre delivery written informed consent, the relatively predictable timeframe for delivery and availability of the placenta, and lower frequency of damage to afterbirth tissues. Parity and gravidity were higher than the national averages. Mean placental weight exceeded the UK average for babies born at term which is \~545 g, and reflected the fact that the majority of births were by cesarean section which tend to result in higher placental weights \[[@CR20]\]. Sixty-one percent of babies were male, and 39% were female. Ninety percent of births were from white Caucasoid mothers. Many other demographic features were similar to the UK national averages. Maternal age was similar to the UK national average of 29.3 years \[[@CR20]\] and neonatal weight was similar to the average UK birth weight of approximately 3,400 g \[[@CR20]\]. As dictated by the scope of this study, all babies in this study were born at term with gestational age ranging from 37 to 41 weeks. Only 3.3% of babies had an Apgar~1min~ score \< 7, indicating the majority of neonates in this study were in overall good health.Table 3Demographics of prenatal and perinatal maternal, obstetric and neonatal observations of UCB donorsCharacteristics (n)RangeNumberPercent (%)Maternal age (years) (52)18--25815.426--353057.7351426.9Parity (49)01326.511836.721530.6≥336.1Gravidity (49)03061.211122.42612.2≥324.1Mode of delivery (48)Vaginal1327.1Caesarean^a^3572.9Neonatal sex (49)Male3061.2Female1938.8Apgar 1 min (48)\<712.0700.08510.491429.2102858.3Apgar 5 min (48)\<712700800900104797.9Apgar 10 min (48)\<7007008009001048100Ethnic group (49)White4489.8Other58.2^a^34 caesarean without labor, 1 caesarean after 1st stage laborTable 4Demographics of perinatal maternal, obstetric and neonatal variablesCharacteristics (n)Mean ± SDRangeGestational age (weeks) (49)39 ± 137--41Neonatal weight (g) (49)3427 ± 4722,620--4,442Placental weight (g) (46)704 ± 144450--1,100Time between onset of stage 1 labor and onset of stage 2 labor (h) (13)4.4 ± 0.71.3--9.2Time between onset of stage 2 labor and delivery of the baby (h) (13)0.8 ± 0.30.1--3.1Time between delivery of the baby and end of stage 3 labor (h) (13)0.2 ± 0.10.0--1.0

Placental weight predicts ECFC content of UCB units {#Sec11}
---------------------------------------------------

Table [5](#Tab5){ref-type="table"} summarizes the mean numbers and the range of ECFC found in the 52 UCB units tested. ECFC-derived cells were confirmed by morphology and phenotype as endothelial in nature (Fig. [1](#Fig1){ref-type="fig"}). The range of ECFC frequencies was from 0 to 375 ECFC/unit with 8 UCB units not forming ECFC and with the mean ECFC numbers being 44.6 ± 9.8 ECFC/UCB unit or 8.2 ± 1.8 ECFC/10^8^ MNC.Table 5Endothelial colony forming cell (ECFC) content of umbilical cord blood unitsCharacteristicsMean ± SEMRangeECFC/UCB unit44.6 ± 9.80--375ECFC/ml0.5 ± 0.10--4.1ECFC/MNC (×10^8^)8.2 ± 1.80--57.1n = 52 UCB unitsFig. 1ECFC-derived cell characteristics. Representative photomicrographs of ECFC-derived colonies cultured from UCB MNCs on **a** d9 of culture (×4 magnification) and **b** d14 (×10 magnification) of culture. Colonies with similar cobblestone morphology were identified in other cultures of UCB. **c** Flow cytometric profile of ECFC-derived cells. Representative graph of median fluorescence intensity (MFI) + SEM (n = 3) using cells from different donors. Antibody isotypes and fluorophores are grouped to compare test antibody staining with isotype control staining

In testing the effect of obstetric factors, skewed data were transformed by taking the Box-Cox transformation to achieve an approximate normal distribution of the data and to stabilize the variance, thereby satisfying the conditions for a valid linear model. Some of the explanatory variables were also transformed to remove excessive skewness. Fitting of a linear model regression was then attempted for the full data set (n = 52) initially using ECFC/UCB as a unit of measurement of ECFC frequency. This was because, of the three experimental outcomes examined for ECFC frequency (per unit, per ml UCB, per 10^8^ MNC), ECFC/UCB unit responded best to transformation i.e. achieved the best approximation of a normal distribution of the data. The effect of multiple obstetric factors was examined starting with all obstetric variables and the least significant variables eliminated from the modeling in a stepwise fashion. Neither combination of the obstetric factors nor any single factor exhibited a statistically significant causal relationship with ECFC frequency/UCB unit. Similar outcomes were obtained from the same analyses with ECFC/ml UCB and ECFC/10^8^ MNC.

An alternative modeling approach was taken by excluding all UCB where EFCF/UCB unit = 0 and analyzing the remaining data using the approach above. With the zeroes omitted, it was possible to find the optimal Box-Cox transformation of the response variable, which had the form (Y\^lambda − 1)/lambda, with lambda = 0.1. Placental weight (range 450--110 g) was the only statistically significant predictor of ECFC frequency (*P*-value = 0.046). No other obstetric factor gave an indication of having a significant effect (Fig. [2](#Fig2){ref-type="fig"}). The following formula if E~pred~ is predicted ECFC/cord blood unit and P is placental weight (g) was devised to predict the ECFC frequency from placental weight.$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
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                \begin{document}$$ {\text{E}}_{\text{pred}} = \left( {1.2421 + \frac{{3.226 \times 10^{3} }}{{{\text{P}}^{2/3} }}} \right)^{10} $$\end{document}$$The function is plotted in Fig. [2](#Fig2){ref-type="fig"} along with 95% prediction interval bands and the measured data points with placental weights lower than 2,000 g have also been added. The range of placental weights was restricted to being less than 2,000 g in order to avoid undue compression of the scale. It is worth noting that the heavier placental weights in fact turn out to lie almost exactly on the prediction curve.Fig. 2Correlation between placental weight and ECFC**.** Model fit (*solid line*) of the correlation between placental weight and ECFC/UCB unit (*P* \< 0.05), 95% confidence intervals are indicated by *dashed lines*

Further, a discriminant analysis approach was taken by awarding a binary variable to ECFC/UCB unit and a fit of a generalized linear model attempted, i.e. UCB units which gave rise to ECFC were awarded a value of one, and those that did not were awarded a value of zero. As above, the effect of multiple obstetric factors was examined starting with all obstetric variables and the least significant variables eliminated from the modeling in a stepwise fashion. By this method, neither combination of the obstetric factors nor any single factor exhibited a statistically significant causal relationship with ECFC frequency/UCB unit.

UCB storage temperatures affect ECFC yield {#Sec12}
------------------------------------------

In addition to examining obstetric factors, we also assessed if UCB storage temperature affected ECFC yield. Since, in accordance with FACT-Netcord standards, we store fresh CBB UCB units for transplantation from the NHS Cord Blood Bank at 22 ± 2°C after collection and do so for up to 24 h before processing by volume reduction \[[@CR18], [@CR21]\], we examined the effects of transient storage of UCB on ECFC yield. R&D UCB units were collected from 25 subjects at random and stored at either 4 ± 2°C or 22 ± 2°C in temperature mapped fridges/incubators for 24 h, then the 'Enumeration of ECFC' procedure was followed as detailed in the "[Materials and methods](#Sec2){ref-type="sec"}".

The data were clearly non-normal and therefore a non-parametric Wilcoxon rank sum test for location difference was carried out with allowance for one pair of tied values in the 4°C group. The *P*-value was 0.0013 and it was therefore concluded that there was a highly significant difference between the two groups. Storage for 24 h at 22°C yielded 4 times more ECFC/CBU than storage for 24 h at 4°C (the ratio of medians was 4.07, the ratio of means was 4.06) (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Effects of short-term storage conditions on yield of ECFC. UCB were stored for either 2 h at 4°C (n = 6), 24 h at 4°C (n = 9) or 24 h at 22°C (n = 10). *Error bars* are SEM. ECFC yields were assessed per **a** UCB unit, **b** ml UCB and **c** MNC (×10^6^) seeded. Wilcoxon statistical analysis showed that storage at 4°C had a significant effect on ECFC yield both for 2 and 24 h (\**P* = 0.0013)

The effect of cryopreservation on ECFC was also examined by comparing ECFC yield from fresh R&D UCB units with their recovery after cryopreservation. To test recovery of ECFC from cryopreservation, MNC were isolated from 20 R&D UCB units as per the 'ECFC enumeration' procedure in the "[Materials and methods](#Sec2){ref-type="sec"}". At the cell pellet stage, before seeding into a 6-well plate, the MNC were split into two samples, one was cryopreserved and the other tested for ECFC as per the 'Enumeration of primary Endothelial Colony Forming Cells' procedure. The cryopreserved sample was stored at −195°C for 2--14 days, and then thawed in the presence of DNase 1 which was used to digest extracellular DNA from lysed neutrophils, and viable MNC numbers determined. MNC were typically \>95% viable. Viable MNC were seeded as per the 'Enumeration of Endothelial Colony Forming Cells' procedure and the resulting ECFC content of the cryopreserved UCB compared with ECFC yield from fresh UCB. Ninety percent of fresh R&D UCB samples generated ECFC compared to 33% of the cryopreserved UCB samples. When the latter 33% of UCB units that formed ECFC in both fresh and frozen UCB samples were compared, the ECFC recovery from cryopreservation was \~50% lower than that found in the original fresh UCB sample (Fig. [4](#Fig4){ref-type="fig"}b). The quality of ECFC was also investigated by examining the proliferative potential of the ECFC-derived cells in a clonal proliferation assay. Endothelial colonies derived from each UCB MNC preparation before and after cryopreservation from the previous experiment were pooled and cultured (p2) and their content of ECFCs which formed colonies of different sizes assessed in the clonogenic assay described in 'Proliferative potential' in the Materials and Methods.Fig. 4UCB ECFC recovery from cryopreservation. **a** Recovery of ECFC from cryopreservation compared with yield from fresh UCB (fresh n = 23, crpv n = 15, *error bars* are SEM). **b** Proliferative potential of recovered ECFC from cryopreservation compared with ECFC proliferative potential from fresh UCB (fresh n = 8, crpv n = 3); *crpv* cryopreserved; LPP, low proliferative potential cells \[[@CR19]\]; HPP, high proliferative potential cells \[[@CR19]\]

ECFC yield from CBB procedures were examined by enumerating ECFC from cryopreserved CBB UCB units and the results presented in Fig. [5](#Fig5){ref-type="fig"}. ECFC yield/ml UCB was sixfold lower in CBB than cryopreserved R&D UCB units indicating ECFC losses during CBB UCB processing procedures (Fig. [5](#Fig5){ref-type="fig"}a). Interestingly, of those ECFC a threefold higher proportion of these were high-proliferative and a 1.4-fold higher proportion were low-proliferative. The remainder (clusters and non-proliferative) was 1.2-fold higher in R&D than CBB UCB (Fig. [5](#Fig5){ref-type="fig"}b). However these findings conflict with the absolute levels of HPP and LPP per volume of UCB (considering CBB UCB exhibited sixfold lower ECFC/ml). Collectively these findings suggest that, qualitatively and quantitatively, CBB and R&D UCB units are comparable in terms of highly proliferative cells. However, there may be the possibility of increasing ECFC yields, and hence highly proliferative ECFC yields, from CBB UCB units as indicated by ECFC/ml UCB.Fig. 5UCB ECFC recovery from cryopreserved R&D and CBB sources. **a** ECFC frequency in UCB (CBB n = 14, R&D n = 15, *error bars* are SEM). **b** Proliferative potential of ECFC by source (CBB n = 3, R&D n = 3). **c** ECFC frequency/cord blood unit versus CD34^+^ cells/UCB unit. *CBB* cord blood bank-sourced UCB units; *R&D* research resource-sourced UCB units; *CBU* cord blood unit; LPP, low proliferative potential cells; HPP, high proliferative potential cells

In CBB UCB units, the relationship between CD34^+^ cell numbers and ECFC was examined by testing for a linear correlation between CB34^+^ cells per UCB unit and ECFC/UCB unit (Fig. [5](#Fig5){ref-type="fig"}c). No correlation was observed (r² = 0.1490) suggesting that CD34^+^ cell content in UCB units would not be good predictor of ECFC content.

Discussion {#Sec13}
==========

The therapeutic potential for ECFC for supporting blood cell reconstitution, vascular engineering, neovasuclarisation and cardiovascular repair has been widely discussed \[[@CR8]\]. In order to fully realize the clinical utility of ECFCs that are known to be present in UCB, we must first understand factors affecting the yield of these cells from UCB. The study presented here focused on whether obstetric factors, transient pre-processing storage and long-term cryopreserved storage could influence the ECFC content of UCB at term, areas which have not previously been fully investigated. Our results demonstrate a positive correlation between placental weight and ECFC content of UCB in the donor population studied. Previous studies have shown that placental weight and weight of the infant at birth positively correlate with TNC count, UCB volume, CD34^+^ cell content and total hematopoietic CFU in UCB (Table [1](#Tab1){ref-type="table"}). Indeed, Ballen et al. \[[@CR22]\] have suggested that each 500 g increase in birth weight contributes to a 28% increase in CD34^+^ cell counts.

However, CD34 has suggested to be both a hematopoietic and endothelial progenitor and mature endothelial marker \[[@CR8]--[@CR10]\], hence, it has been difficult to correlate CD34^+^ cell numbers in peripheral blood or UCB with ECFC content in normal individuals. ECFCs are thought to represent a minor proportion of the CD34^+^ cells which do not express CD45 \[[@CR8], [@CR15], [@CR23], [@CR24]\]. For the CBB UCB units used here, the ISHAGE protocol for CD34^+^ enumeration reported total CD34^+^CD45^dim^ which probably do not best represent ECFC. Indeed, in the present study, we observed no correlation between CD34^+^ expressing cells and ECFC frequency. Currently, UCB banks select UCB units for HSC transplant based on CD34^+^ cell content thresholds and the requirement for maximal ethnic diversity. However, in light of the current findings, UCB units reported as having low CD34^+^ content according to the ISHAGE protocol may still be a useful source of ECFC and so should not be discarded.

We saw no correlations with many of the obstetric factors examined including parity, mode of delivery or infant gender. As the donor population was skewed towards uncomplicated pregnancies and deliveries at term from Caucasoid mothers, an analysis of a wider range of Apgar scores, gestational ages and ethnicity on ECFC content of UCB was not possible in our study. It was not possible to analyze the effect of ethnic origin on ECFC content of UCB in this study, yet this is a factor of particular relevance to UCB banking especially in the UK where adult bone marrow registries lack ethnic diversity of donors. Ethnicity has been shown to have no significant effect on TNC in relation to HSC/HPC UCB banking and transplantation \[[@CR25]\] while Caucasoid births produce higher UCB CD34^+^ yields \[[@CR26]\]. In those ethnic groups where placental weight is lower than in white Caucasoid donors \[[@CR4]\], the ECFC numbers may well be lower than in term UCB units from larger white Caucasoid donors.

Interestingly, our studies have allowed us to develop a formula to predict the ECFC frequency from placental weight with a 95% confidence interval for the predicted value and this formula could be used in the future with defined ethnic groups to confirm its robustness. Baker et al. \[[@CR15]\] have suggested that ECFC content and proliferative ability in UCB may contribute to organogenesis in for example the renal glomerulus and retina and the need to significantly expand the pulmonary microvasculature during late gestation and early post natal life. It would thus seem reasonable to assume that the rate of development may also correlate with the UCB content of ECFC and proangiogenic hematopoietic cells, both of which have key roles in neovasculogenesis \[[@CR8], [@CR24]\].

In addition to assessing obstetric factors, we also analyzed the effects of transient storage temperatures on ECFC yield from UCB. Current FACT-Netcord standards support transient storage and transport of UCB units for subsequent HSC transplantation prior to processing at 22 ± 2°C \[[@CR1], [@CR2], [@CR4]\]. Our own practice at the NHS Cord Blood Bank is to maintain UCB units at these temperatures for up to 24 h before processing is initiated \[[@CR27]\]. This is because initial studies involving human HPCs demonstrated that UCB storage at both 4°C and room temperature for up to 24 h led to little or no cell loss \[[@CR29]--[@CR31]\], with slightly higher counts for UCB stored at room temperature \[[@CR29]\] and so, consensus is that there is no significant effect on TNC and CD34^+^ cell viability and hematopoietic CFU when UCB is stored at room temperature for 24 h. However, storage conditions for longer times are conflicting. Recent studies \[[@CR32]\] suggest that, with the exception of viable CD34^+^ cells, there is a significant decrease in TNC, MNC and CD45^+^ cell viability between 72 and 96 h and, with the exception of viable CD34^+^ cells and CFU-GM, the reductions are significantly higher with room temperature as opposed to 4°C storage pre-processing. Our studies revealed that we could recover higher numbers of ECFC if UCB was stored at 22 ± 2°C as opposed to 4°C storage for 24 h. Our findings may be explained by the fact that storage at room temperature instead of refrigeration avoids rapid cooling and subsequent warming of the blood which leads to temperature shock and can trigger cellular apoptosis \[[@CR14]\]. To our knowledge, similar studies concerning ECFC recovery have not been done.

In agreement with Vanneaux et al. \[[@CR17]\], our studies indicate that cryopreservation of UCB MNCs, even after room temperature storage for up to 24 h, significantly affected ECFC recovery. However, the quantity of HPP ECFCs was less affected by cryopreservation than the overall ECFC yield from UCB. If proliferative potential of ECFC is of clinical importance in future therapeutic applications, then indeed HPP ECFC yield is the more important criteria.

As well as the limitations described above, this and similar studies are also limited by the lack a specific biomarker for enumerating ECFC in UCB, particularly in light of the lack of a correlation observed with CD34. An important question from the clinical perspective is: 'how many ECFCs are required for a useful therapeutic dose?' which raises the possibility of expanding and banking ECFC from UCB as a further transplant option. We are still some way from using banked UCB units as a source of ECFCs in the clinic where they may promote hematopoietic engraftment and tissue repair. However, UCB transplantation and UCB banking are both rapidly evolving fields and in future, any readily available information regarding the efficacy of stem/progenitor cells in such units may impact significantly on the quality of units selected for transplantation and research. With this in mind, further studies on more diverse populations of donors are warranted to fully determine which obstetric factors affect ECFC numbers in UCB.

This work presents independent research commissioned by the National Institute for Health Research (NIHR) under its Program Grants scheme. The views expressed in this publication are those of the author (s) and not necessarily those of the NHS, the NIHR or the Department of Health. This work was supported by research funding from NHS Blood and Transplant (GT, JS, and SMW), National Institutes of Health Research (SMW, GT, and CPK), Restore Burn and Wound Research (JK, SMW), the Cord Blood Charity (KEC, SMW, JS), the University of Melbourne (SJL) and the EU Framework VII Cascade grant (SMW). JK is a recipient of a Duke of Kent Research Fellowship. The sponsors of this study are public, non profit organizations that support science in general. They had no role in gathering, analyzing or interpreting the data. The authors wish to acknowledge Dr D Lunn of the Oxford University Statistical Consultancy Service, who carried out the statistical analyses, Mrs. Sandra Britt and Ms Janice Gotobed, who collected the R&D UCB units and the staff of the NHS Cord Blood Bank for providing CBB UCB units.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
